Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: Second Trial of Heparin and Aspirin Reperfusion Therapy (HART II)

Circulation

Volumn 104, Issue 6, 2001, Pages 648-652

  Ross, Allan M ^a,e   Molhoek, Peter ^b   Lundergan, Conor ^a   Knudtson, Merrill ^c   Draoui, Yasmine ^a   Regalado, Lorna ^a   Le Louer, Veronique ^d   Bigonzi, Frederique ^d   Schwartz, Whitney ^d   De Jong, Egbert ^d   Coyne, Karin ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b MEDISCH SPECTRUM TWENTE   (Netherlands)

^c UNIVERSITY OF CALGARY   (Canada)

^d SANOFI   (France)

^e GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Heparin; Myocardial infarction; Reperfusion; Thrombolysis; Trials

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ACUTE HEART INFARCTION; ADJUVANT THERAPY; ADULT; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY RECANALIZATION; FEMALE; FIBRINOLYSIS; HEART MUSCLE REPERFUSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS;

EID: 0035822605     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/hc3101.093866     Document Type: Article

References (27)

1. A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM): Mortality, morbidity, and infarct size at 21 days
2. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: Overview of results on mortality, reinfarction and side effects from 33 randomised trials
3. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction: Gruppo Italiano per lo Studio della Streptochinasi nell'infarcto Miocardico (GISSI)
4. Intravenous streptokinase given within 0-4 hours of onset of myocardial infarction reduces mortality in ISIS-2
5. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2
6. Double-blind randomised trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction
7. Long-term effects of intravenous anistreplase in acute myocardial infarction: Final report of the AIMS study
8. Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: Retrospective analysis of four German multicenter studies
9. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction
10. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction
11. The use of low-molecular-weight heparins in cardiology
12. Prothrombin activation by thrombolytic agents
13. Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: Results from the GUSTO-I Trial
14. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in myocardial Infarction (TIMI) 9B Trial
15. Low-molecular-weight heparin for the treatment of venous thromboembolism
16. New antithrombotic agents for the prevention and treatment of deep vein thrombosis
17. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia
18. Comparison of low molecular weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in unstable coronary artery disease study (FRIC)
19. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX. I. S. (FRAxiparine in Ischaemic Syndrome)
20. A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease
21. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: Results of the Thrombolysis In Myocardial Infarction (TIMI 11B) trial
22. Low-molecular-weight heparins in acute myocardial infarction: Rationale and results of a pilot study
23. Dose-ranging trial of enoxaparin for unstable angina: Results of TIMI 11A
24. Randomized Trial of Low Molecular Weight Heparin (Dalteparin) in Prevention of Left Ventricular Thrombus Formation after Acute Anterior Myocardial Infarction: The Fragmin in Acute Myocardial Infarction (FRAMI) Study
25. Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction: A pilot study: Biochemical markers in acute coronary syndromes (BIOMACS II)
26. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: Results from the ESSENCE randomized trial
27. Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)